CN109219614B - Cd200突变体及其用途 - Google Patents

Cd200突变体及其用途 Download PDF

Info

Publication number
CN109219614B
CN109219614B CN201780028505.0A CN201780028505A CN109219614B CN 109219614 B CN109219614 B CN 109219614B CN 201780028505 A CN201780028505 A CN 201780028505A CN 109219614 B CN109219614 B CN 109219614B
Authority
CN
China
Prior art keywords
protein
wild
proteins
seq
mutated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780028505.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN109219614A (zh
Inventor
P·赫胥黎
J·谢里丹
J·希尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ducentis Biotherapeutics Ltd
Original Assignee
Ducentis Biotherapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ducentis Biotherapeutics Ltd filed Critical Ducentis Biotherapeutics Ltd
Publication of CN109219614A publication Critical patent/CN109219614A/zh
Application granted granted Critical
Publication of CN109219614B publication Critical patent/CN109219614B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201780028505.0A 2016-05-10 2017-05-10 Cd200突变体及其用途 Active CN109219614B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1608197.8A GB201608197D0 (en) 2016-05-10 2016-05-10 Novel proteins
GB1608197.8 2016-05-10
PCT/GB2017/051303 WO2017194941A1 (en) 2016-05-10 2017-05-10 Cd200 mutant and its uses

Publications (2)

Publication Number Publication Date
CN109219614A CN109219614A (zh) 2019-01-15
CN109219614B true CN109219614B (zh) 2022-05-24

Family

ID=56297468

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780028505.0A Active CN109219614B (zh) 2016-05-10 2017-05-10 Cd200突变体及其用途

Country Status (15)

Country Link
US (1) US11203628B2 (https=)
EP (1) EP3455247A1 (https=)
JP (1) JP6997767B2 (https=)
KR (2) KR102498901B1 (https=)
CN (1) CN109219614B (https=)
AU (1) AU2017264825B2 (https=)
BR (1) BR112018073280A2 (https=)
CA (1) CA3023601A1 (https=)
EA (1) EA201892554A1 (https=)
GB (1) GB201608197D0 (https=)
IL (1) IL262846B2 (https=)
MX (1) MX386295B (https=)
SG (1) SG11201809677XA (https=)
WO (1) WO2017194941A1 (https=)
ZA (1) ZA201807079B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201608197D0 (en) 2016-05-10 2016-06-22 Ducentis Biotherapeutics Ltd Novel proteins
KR102186780B1 (ko) 2019-02-18 2020-12-04 박주현 비행부와 탑승부를 분리하여 축으로 결합한 유인드론
CN110859951A (zh) * 2019-09-23 2020-03-06 中国药科大学 Cd200蛋白和cd200融合蛋白在制备治疗银屑病药物中的应用
GB202115803D0 (en) * 2021-11-03 2021-12-15 Ducentis Biotherapeutics Ltd Novel proteins
AU2023265174A1 (en) * 2022-05-06 2024-12-12 Ducentis Biotherapeutics Limited Novel cd200 fusion proteins
CN119365483A (zh) * 2022-05-06 2025-01-24 杜森蒂斯生物治疗有限公司 新型cd200融合蛋白
GB2626300A (en) * 2022-12-08 2024-07-24 Ducentis Biotherapeutics Ltd Mutated CD200 proteins and methods of use therof
GB202303291D0 (en) 2023-03-07 2023-04-19 Secr Defence Medicament and medicament combination for use in the treatment of infectious disease
GB202306711D0 (en) * 2023-05-05 2023-06-21 Ducentis Biotherapeutics Ltd Novel proteins
WO2025106841A1 (en) * 2023-11-15 2025-05-22 The University Of Chicago Methods and compositions for inducing antigen specific tolerance

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999024565A1 (en) * 1997-11-07 1999-05-20 Transplantation Technologies Inc. Methods and compositions for immunomodulation
WO2002042332A2 (en) * 2000-11-22 2002-05-30 Trillium Therapeutics Inc. Truncated cd200
CN101370525A (zh) * 2005-08-19 2009-02-18 艾博特公司 双重可变结构域免疫球蛋白及其用途
CN102448982A (zh) * 2009-03-31 2012-05-09 华盛顿大学 用于调节靶细胞上补体调节蛋白的活性的组合物和方法
CN102906115A (zh) * 2010-01-11 2013-01-30 阿雷克森制药公司 在经抗cd200抗体治疗的人体内的免疫调节效应的生物标记

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7223729B2 (en) 1997-11-07 2007-05-29 Trillium Therapeutics Inc. Methods of treating allergy by administering a CD200 protein
MXPA01010480A (es) * 1999-04-13 2002-03-27 Schering Corp Usos novedosos de la proteina 0x2 de mamifero y reactivos relacionados.
EP1261743A2 (en) * 2000-03-07 2002-12-04 Hyseq, Inc. Novel nucleic acids and polypeptides
AU2008206502A1 (en) * 2007-01-11 2008-07-24 Boehringer Ingelheim International Gmbh CD200 and its receptor, CD200R, modulate bone mass via the differentiation of osteoclasts
GB201608197D0 (en) 2016-05-10 2016-06-22 Ducentis Biotherapeutics Ltd Novel proteins

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999024565A1 (en) * 1997-11-07 1999-05-20 Transplantation Technologies Inc. Methods and compositions for immunomodulation
WO2002042332A2 (en) * 2000-11-22 2002-05-30 Trillium Therapeutics Inc. Truncated cd200
CN101370525A (zh) * 2005-08-19 2009-02-18 艾博特公司 双重可变结构域免疫球蛋白及其用途
CN102448982A (zh) * 2009-03-31 2012-05-09 华盛顿大学 用于调节靶细胞上补体调节蛋白的活性的组合物和方法
CN102906115A (zh) * 2010-01-11 2013-01-30 阿雷克森制药公司 在经抗cd200抗体治疗的人体内的免疫调节效应的生物标记

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
《Structures of CD200/CD200 Receptor Family and Implications for Topology, Regulation, and Evolution》;Deborah Hatherley等;《Stucture》;20130507;第21卷(第5期);第820-832页 *

Also Published As

Publication number Publication date
US11203628B2 (en) 2021-12-21
BR112018073280A2 (pt) 2019-03-19
EA201892554A1 (ru) 2019-04-30
US20190367580A1 (en) 2019-12-05
GB201608197D0 (en) 2016-06-22
CA3023601A1 (en) 2017-11-16
IL262846A (en) 2018-12-31
KR20230025937A (ko) 2023-02-23
IL262846B2 (en) 2023-02-01
KR102689460B1 (ko) 2024-07-26
NZ747665A (en) 2025-10-31
JP6997767B2 (ja) 2022-03-04
IL262846B (en) 2022-10-01
EP3455247A1 (en) 2019-03-20
KR102498901B1 (ko) 2023-02-10
AU2017264825A1 (en) 2018-11-15
SG11201809677XA (en) 2018-11-29
KR20190003761A (ko) 2019-01-09
AU2017264825B2 (en) 2021-04-08
CN109219614A (zh) 2019-01-15
ZA201807079B (en) 2019-07-31
MX2018013778A (es) 2019-08-01
WO2017194941A1 (en) 2017-11-16
JP2019518788A (ja) 2019-07-04
MX386295B (es) 2025-03-18

Similar Documents

Publication Publication Date Title
CN109219614B (zh) Cd200突变体及其用途
WO2019062642A1 (zh) 靶向pd-1或pd-l1且靶向vegf家族的双靶向融合蛋白及其用途
JP2018519834A (ja) ヒトＦｃ受容体に結合する融合タンパク質
TWI868739B (zh) 靶向kras g12v突變多肽的t細胞受體及其用途
CN116583294A (zh) 抗炎细胞因子及其使用方法
CN108473551A (zh) 高亲和力IgE受体的α链(FceRIa)
JP2025515191A (ja) 新規ｃｄ２００融合タンパク質
US20250026805A1 (en) Novel proteins
JP2024544972A (ja) Ｓｉｒｐ１ａ及びｃｄ４０ｌベースのキメラタンパク質
CN111234019B (zh) 抗ctla-4纳米抗体、药物组合物及其应用
JP7813054B2 (ja) コイルドコイル融合タンパク質
EA042608B1 (ru) Мутант cd200 и его применения
US12528840B2 (en) Transcription active complex targeting cancer drug from viral protein sequence
US20260116946A1 (en) Novel cd200 fusion proteins
US20260116951A1 (en) Novel cd200 fusion proteins
CN119365483A (zh) 新型cd200融合蛋白
CA3248283A1 (en) IL-15 AGONISTS FOR TREATING CANCER
CN110156897A (zh) 一种包含TRAIL和IgG结合结构域的融合蛋白及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant